Latest News - InSite Vision

Wednesday, November 04, 2015 | Acquisitions/Mergers, InSite Vision

Sun Pharma Completes Acquisition of InSite Vision

Sun Pharmaceutical Industries announced the successful completion of its acquisition of InSite Vision. The acquisition was completed by means of a short-form merger under Delaware law. Post the …

Read the full story

Tuesday, September 15, 2015 | Acquisitions/Mergers, InSite Vision

InSite Vision and Sun Pharma Enter into Merger Agreement

A wholly owned subsidiary of Sun Pharma will acquire InSite Vision in an all-cash transaction for $0.35 per share, or approximately $48 million in aggregate equity value. The transaction has been appr…

Read the full story

Monday, September 07, 2015 | Acquisitions/Mergers, InSite Vision

InSite Vision Determines that New Unsolicited Offer Constitutes a “Company Superior Proposal”

InSite Vision announced that InSite’s board of directors has determined that the previously announced unsolicited offer from an unnamed global pharmaceutical company to acquire all outstanding s…

Read the full story

Friday, September 04, 2015 | Acquisitions/Mergers, InSite Vision

InSite Vision Receives Second Unsolicited Acquisition Proposal for $0.35 per Share From a Global Pharmaceutical Company

InSite Vision announced that the company has received a second unsolicited proposal from a global pharmaceutical company to acquire all outstanding shares of InSite Vision common stock at an increased…

Read the full story

Thursday, September 03, 2015 | Corporate Lawsuits, InSite Vision

InSite Vision Named in BromSite Patent Lawsuit; Company Believes Lawsuit Is Without Merit

InSite Vision announced that Johnson Matthey Pharmaceutical Materials has filed a patent lawsuit in the United States District Court for the District of Delaware in connection with activities relating…

Read the full story

Thursday, August 27, 2015 | Acquisitions/Mergers, InSite Vision, QLT

InSite Vision and QLT Amend Merger Agreement

InSite Vision and QLT entered into a revised merger agreement under which QLT will acquire InSite, and in doing so, fend off an unsolicited offer from an unnamed pharmaceutical company. Under the term…

Read the full story

Friday, August 21, 2015 | Acquisitions/Mergers, InSite Vision, QLT

InSite Vision: Unsolicited Offer to Acquire InSite for $0.25 in Cash Constitutes a “Company Superior Proposal” than QLT's Offer

InSite Vision announced that InSite’s board of directors determined that the previously announced unsolicited offer from a multi-national pharmaceutical company to acquire InSite for $0.25 per s…

Read the full story

Tuesday, August 18, 2015 | Cataract Surgery, InSite Vision

InSite Vision Announces FDA Acceptance of NDA Filing for BromSite

InSite Vision announced that the FDA, in a day-74 letter, has accepted for review InSite’s new drug application (NDA) for BromSite (0.075% bromfenac) for the treatment of inflammation and preven…

Read the full story

Monday, August 10, 2015 | Acquisitions/Mergers, InSite Vision, QLT

InSite Vision Receives Unsolicited Proposal from a Multi-National Pharmaceutical Company

InSite Vision announced that the company has received an unsolicited proposal from a multi-national pharmaceutical company to acquire all outstanding shares of InSite Vision common stock at a price of…

Read the full story

Thursday, June 11, 2015 | Cataract Surgery, InSite Vision

InSite Vision Announces Completion of the New Drug Application Submission to the FDA for BromSite

InSite Vision announced that it has completed the submission for a new drug application (NDA) to the FDA for BromSite for the treatment of inflammation and prevention of pain in cataract surgery, acco…

Read the full story

Monday, June 08, 2015 | Acquisitions/Mergers, InSite Vision

QLT to Acquire InSite Vision in All-Stock Deal

QLT has signed a definitive agreement to buy InSite Vision for $0.178 per share in an all-stock deal. QLT says the merger will create a diversified, pure-play, late-stage ophthalmic pharmaceutic…

Read the full story